Skip to main content
Equibles
ABBV logo

ABBV · AbbVie Inc. · Webcasts, Transcripts & Audio

Track ABBV — free

Use ABBV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABBV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$286.00 +0.36 (+0.13%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$506.00B
Shares
1.77B
Volume · Oct 26 4.32M Avg daily vol (3M) 4.86M

AbbVie Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for AbbVie Inc. (ABBV), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-30
AbbVie Inc. (ABBV) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
AbbVie Inc. (ABBV) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
AbbVie Inc. (ABBV) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-31
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
Confident tone Oncology portfolio Skyrizi franchise expansion Immunology and Humira decline
Revenue
$16.99B
▲ 10.2% YoY
Diluted EPS
$2.03
▲ 290.4% YoY
Gross margin
74.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-22
AbbVie Inc. (ABBV) June 22, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-09
AbbVie Inc. (ABBV) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-13
AbbVie Inc. (ABBV) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-29
AbbVie Inc. (ABBV) Q1 2026 Earnings Call Transcript
Confident tone Skyrizi (Risankizumab) commercial performance Rinvoq (Upadacitinib) growth and label expansion Neuroscience portfolio (Migraine, Vraylar, Parkinson's)
Revenue
$15.00B
▲ 12.4% YoY
Diluted EPS
$0.39
▼ 45.8% YoY
Gross margin
71.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-04
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
Confident tone Skyrizi and Rinvoq (Immunology Franchise) Neuroscience / Psychiatry Assets Oncology Portfolio (including EMRELIS, Epkinly)
Revenue
$16.62B
▲ 10% YoY
Diluted EPS
$1.02
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-31
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
Confident tone Skyrizi and Rinvoq immunology growth Pipeline and R&D investment Aesthetics softness
Revenue
$15.78B
▲ 9.1% YoY
Diluted EPS
$0.10
▼ 88.6% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
Confident tone Skyrizi and Rinvoq (ex-HUMIRA immunology growth) Rinvoq pipeline expansion (GCA, alopecia areata, vitiligo) Business development and external innovation
Revenue
$15.42B
▲ 6.6% YoY
Diluted EPS
$0.52
▼ 32.5% YoY
Gross margin
71.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-25
AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript
Confident tone Ex-Humira Growth Platform (Skyrizi & Rinvoq) R&D Pipeline & External Innovation Aesthetics Headwinds
Revenue
$13.34B
▲ 8.4% YoY
Diluted EPS
$0.72
▼ 6.5% YoY
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-31
AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript
Confident tone Aesthetics Market Challenges Neuroscience Franchise Oncology Pipeline
Revenue
$15.10B
▲ 5.6% YoY
Diluted EPS
$-0.02
▼ 104.3% YoY
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
AbbVie Inc. (ABBV) Q3 2024 Earnings Call Transcript
Confident tone Neuroscience franchise build-out Skyrizi commercial momentum Rinvoq growth and label expansion
Revenue
$14.46B
▲ 3.8% YoY
Diluted EPS
$0.88
▼ 12% YoY
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-25
AbbVie Inc. (ABBV) Q2 2024 Earnings Call Transcript
Confident tone Immunology (Skyrizi/Rinvoq) growth Humira biosimilar erosion Aesthetics (Allergan) business
Revenue
$14.46B
▲ 4.3% YoY
Diluted EPS
$0.77
▼ 32.5% YoY
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-26
AbbVie Inc. (ABBV) Q1 2024 Earnings Call Transcript
Confident tone Growth Platform (ex-Humira) Skyrizi Commercial Performance Financial Guidance and EPS
Revenue
$12.31B
▲ 0.7% YoY
Diluted EPS
$0.77
▲ 492.3% YoY
Gross margin
66.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-02
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript
Confident tone Skyrizi and Rinvoq performance and outlook M&A: ImmunoGen and Cerevel acquisitions Regulatory/legislative risks (IRA, Part D redesign, GILTI)
Revenue
$14.30B
▼ 5.4% YoY
Diluted EPS
$0.46
▼ 66.7% YoY
Gross margin
60.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-27
AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript
Revenue
$13.93B
▼ 6% YoY
Diluted EPS
$1.00
▼ 54.8% YoY
Gross margin
53.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
AbbVie Inc. (ABBV) Q2 2023 Earnings Call Transcript
Revenue
$13.87B
▼ 4.9% YoY
Diluted EPS
$1.14
▲ 123.5% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
AbbVie Inc. (ABBV) Q1 2023 Earnings Call Transcript
Revenue
$12.22B
▼ 9.7% YoY
Diluted EPS
$0.13
▼ 94.8% YoY
Gross margin
67.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-09
AbbVie Inc. (ABBV) Q4 2022 Earnings Call Transcript
Revenue
$15.12B
▲ 1.6% YoY
Diluted EPS
$1.38
▼ 38.9% YoY
Gross margin
72.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-28
AbbVie Inc. (ABBV) Q3 2022 Earnings Call Transcript
Revenue
$14.81B
▲ 3.3% YoY
Diluted EPS
$2.21
▲ 24.2% YoY
Gross margin
66.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-29
AbbVie Inc. (ABBV) Q2 2022 Earnings Call Transcript
Revenue
$14.58B
▲ 4.5% YoY
Diluted EPS
$0.51
▲ 21.4% YoY
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-29
AbbVie Inc. (ABBV) Q1 2022 Earnings Call Transcript
Revenue
$13.54B
▲ 4.1% YoY
Diluted EPS
$2.51
▲ 26.1% YoY
Gross margin
70.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
AbbVie Inc. (ABBV) Q4 2021 Earnings Call Transcript
Revenue
$14.89B
▲ 7.4% YoY
Diluted EPS
$2.26
▲ 22500% YoY
Gross margin
71.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-29
AbbVie Inc. (ABBV) Q3 2021 Earnings Call Transcript
Revenue
$14.34B
▲ 11.2% YoY
Diluted EPS
$1.78
▲ 38% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-30
AbbVie Inc. (ABBV) Q2 2021 Earnings Call Transcript
Revenue
$13.96B
▲ 33.9% YoY
Diluted EPS
$0.42
Gross margin
67.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-30
AbbVie Inc. (ABBV) Q1 2021 Earnings Call Transcript
Revenue
$13.01B
▲ 50.9% YoY
Diluted EPS
$1.99
▼ 1.5% YoY
Gross margin
67.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
AbbVie Inc. (ABBV) Q4 2020 Earnings Call Transcript
Revenue
$13.86B
▲ 59.2% YoY
Diluted EPS
$0.01
▼ 99.5% YoY
Gross margin
66.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-30
AbbVie Inc. (ABBV) Q3 2020 Earnings Call Transcript
Revenue
$12.90B
▲ 52.2% YoY
Diluted EPS
$1.29
▲ 2.4% YoY
Gross margin
60.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
AbbVie Inc. (ABBV) Q2 2020 Earnings Call Transcript
Revenue
$10.43B
▲ 26.3% YoY
Diluted EPS
$-0.46
▼ 193.9% YoY
Gross margin
64.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-01
AbbVie Inc. (ABBV) Q1 2020 Earnings Call Transcript
Revenue
$8.62B
▲ 10.1% YoY
Diluted EPS
$2.02
▲ 22.4% YoY
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-07
AbbVie Inc. (ABBV) Q4 2019 Earnings Call
Revenue
$8.70B
▲ 4.8% YoY
Diluted EPS
$1.88
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–33 of 33 webcasts
Key facts CIK 1551152 CUSIP 00287Y109 13F (30d) 1507 filings 1452 filers Visit website Investor relations